Back to results
US 2019/0314410 A1Published application
Chimeric receptor t cell treatment using characteristics of the tumor microenvironment
AssigneeKite Pharma, Inc.
InventorsJohn M. Rossi, Adrian Bot
Life of this patent
Estimating the term…
Abstract
The disclosure provides methods of treating a malignancy comprising administering an effective dose of a chimeric receptor (e.g., CAR or TCR) genetically modified T cell immunotherapy. Some aspects of the disclosure relate to methods of characterizing the pre-infusion tumor microenvironment and determining an effective dose of a T cell immunotherapy.
Claims20
A method of treating a malignancy in a patient comprising:
- (a) analyzing a tumor biopsy from the patient to characterize the tumor microenvironment;
- and
- (b) administering an effective dose of T cells comprising one or more chimeric receptors to the patient, wherein the effective dose is determined using the characteristics of the tumor microenvironment.
A method of determining whether a patient will respond to chimeric receptor treatment comprising:
- (a) analyzing a tumor biopsy from the patient to characterize the tumor microenvironment using a gene expression profile;
- (b) determining an immune score based on the gene expression profile;
- and
- (c) determining if the patient will respond to chimeric receptor treatment based on the immune score.
1 more element
A method of determining whether a patient will respond to chimeric receptor treatment comprising:
- (a) obtaining a tumor biopsy from a patient prior to treatment;
- (b) analyzing the tumor biopsy to characterize the tumor microenvironment;
- and
- (c) determining if the patient will respond to chimeric receptor treatment based on the characteristics of the tumor microenvironment.
1 more element
Dependencies are inferred from the claim text.